Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations
Open Access
- 1 December 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (12) , 6085-6096
Abstract
The current emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis calls for novel treatment strategies. Recently, BlaC, the principal β-lactamase ofMycobacterium tuberculosis, was recognized as a potential therapeutic target. The combination of meropenem and clavulanic acid, which inhibits BlaC, was found to be effective against even extensively drug-resistantM. tuberculosisstrains when testedin vitro. Yet there is significant concern that drug resistance against this combination will also emerge. To investigate the potential of BlaC to evolve variants resistant to clavulanic acid, we introduced substitutions at important amino acid residues ofM. tuberculosisBlaC (R220, A244, S130, and T237). Whereas the substitutions clearly led toin vitroclavulanic acid resistance in enzymatic assays but at the expense of catalytic activity, transformation of variant BlaCs into anM. tuberculosisH37Rv background revealed that impaired inhibition of BlaC did not affect inhibition of growth in the presence of ampicillin and clavulanate. From these data we propose that resistance to β-lactam–β-lactamase inhibitor combinations will likely not arise from structural alteration of BlaC, therefore establishing confidence that this therapeutic modality can be part of a successful treatment regimen againstM. tuberculosis.Keywords
This publication has 68 references indexed in Scilit:
- Structures of the Michaelis Complex (1.2 Å) and the Covalent Acyl Intermediate (2.0 Å) of Cefamandole Bound in the Active Sites of the Mycobacterium tuberculosis β-Lactamase K73A and E166A Mutants,Biochemistry, 2010
- Biochemical and Structural Characterization of Mycobacterium tuberculosis β-Lactamase with the Carbapenems Ertapenem and DoripenemBiochemistry, 2010
- Mechanistic Basis for the Emergence of Catalytic Competence against Carbapenem Antibiotics by the GES Family of β-LactamasesJournal of Biological Chemistry, 2009
- Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM‐1 β‐lactamaseProtein Science, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Different Intermediate Populations Formed by Tazobactam, Sulbactam, and Clavulanate Reacting with SHV-1 β-Lactamases: Raman Crystallographic EvidenceJournal of the American Chemical Society, 2009
- GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular SimulationJournal of Chemical Theory and Computation, 2008
- Irreversible Inhibition of the Mycobacterium tuberculosis β-Lactamase by ClavulanateBiochemistry, 2007
- Crystal Structure of KPC-2: Insights into Carbapenemase Activity in Class A β-Lactamases,Biochemistry, 2007
- [20] Processing of X-ray diffraction data collected in oscillation mode1997